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Abstract
The aim of this study was to evaluate the nuclear expression of histone methyltransferase enhancer of zeste homolog 2 (EZH2) in
endocervical neoplastic lesions such as invasive endocervical adenocarcinoma (ECA) and cervical in situ adenocarcinoma (AIS) in
comparison with normal endocervix and non-neoplastic counterparts. A total of 54 consecutive neoplastic cases (37 ECA, 17 AIS)
and 32 non-neoplastic endocervical lesions (15 reactive atypia, 9 microglandular hyperplasia, 3 tuboendometrioid metaplasia, 3
tunnel cluster, 2 endometriosis) were included in the study with adjacent normal endocervix if present. EZH2 immunoreactivity was
evaluated semiquantitatively by three independent experts in lesions and adjacent normal glandular epithelium as well. EZH2
expression was defined robust if at least two of the three experts rated partial or diffuse positivity. Robust EZH2 expression was
statistically compared among the neoplastic, non-neoplastic, and normal glandular epithelium samples. Diagnostic test capability of
robust EZH2 expression was calculated. Fifty-three out of the 54 neoplastic cases (98%) showed robust EZH2 expression. Robust
EZH2 expression was significantly less often (4 out of 32 cases, 12.5%) found in the non-neoplastic endocervical lesions
(p < 0.0001) and never (0 out of 66 samples) in the adjacent normal glandular epithelium. Robust EZH2 overexpression had a
sensitivity and specificity of over 95% in detecting neoplastic lesions versus non-neoplastic lesions or normal glandular epithelium.
EZH2 may play a role in the pathogenesis of endocervical neoplasia, and the detection of robust expression of EZH2 might be a
useful differential diagnostic tool in problematic endocervical lesions in histology and cytology as well.
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Introduction
Endocervical adenocarcinoma (ECA) is the secondmost com-
mon histological type of cervical cancer; it comprises approx-
imately 20 to 25% of cervical malignancies [1] and has a
poorer prognosis than squamous cell carcinoma [2]. Cervical
adenocarcinomas and their precursor lesions are heteroge-
neous and have several different subtypes, most of them close-
ly related to HR-HPVs [3].
It is well established that the pRB pathway is involved in
the pathogenesis of cervical cancer due to the interaction with
HR-HPV E7 oncoproteins leading to genomic instability [4].
It is also known that viral E6/E7 oncoproteins may interact
with different types of epigenetic enzymes, such as p300,
CBP, and pCAF, which can be involved in the oncogenesis
[5].
Enhancer of zeste homolog 2 (EZH2), a member of the
polycomb group of genes, is a methyltransferase that methyl-
ates histone H3 on gene promoters and plays a critical role in
epigenetic gene silencing and chromatin remodeling. EZH2
inhibits cell differentiation and targets gene expression. In
conjunction with the p53 protein, it induces tumor cell prolif-
eration, metastasis, and immortalization [6].
Recent studies focused on the role of EZH2 in the patho-
genesis of various adenocarcinomas as well as malignant tu-
mors of the breast [7], lung [8], stomach [9], colon [10],
pancreatobiliary tract [11], liver [12], thyroid gland [13], pros-
tate [14], bladder [15], uterus [16], and ovary [17]. High ex-
pression of EZH2 was shown to be associated with tumor
aggressiveness and was suggested as a potential differential
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diagnostic marker [8, 10–17]. In the cervix, one study reported
overexpression and the possible prognostic significance of
EZH2 in squamous cell carcinoma [18].
Expression of EZH2 in endocervical neoplastic lesions is
yet unknown. In this study, we examined EZH2 expression in
ECA and AIS, compared with non-neoplastic cervical lesions
and normal glandular epithelium.
Materials and methods
Patients and specimen collection
Consecutive patients from 2007 to 2017 with a diagnosis of
endocervical neoplastic lesions (ECA and/or AIS with or
without cervical intraepithelial neoplasia) and patients with
benign findings as a control group were collected from the
archives of the Department of Pathology, University of Pécs,
Hungary, and Department of Pathology, County Hospital
Tolna, János Balassa Hospital, Szekszárd, Hungary.
Formalin-fixed and paraffin-embedded tissue samples
from biopsy, cone, or hysterectomy specimens were available
along with the HE slides in each case. Slides were re-
evaluated to select the most feasible specimens for immuno-
histochemistry for each patient. We classified endocervical
adenocarcinomas based on the International Endocervical
Adenocarcinoma Criteria and Classification (IECC) [19].
This work has been approved by the local ethical commit-
tee (number of permission: PTE/57682/2017).
Immunohistochemistry
Prior to immunohistochemistry, formalin-fixed paraffin-em-
bedded tissue specimens were cut into 4-μm-thick sections
and dried for 20 min at 60 °C.
Immunostaining was performed using Leica Bond Max
autostainer (Leica Biosystems, Bannockburn, IL) and Leica
Bond Polymer Refine Detection Kit (Leica Biosystems,
Newcastle Upon Tyne, UK). The mouse monoclonal EZH2
antibody (clone 6A10) was obtained from Leica Biosystems
(Newcastle Upon Tyne, UK) and used at a dilution of 1:200.
The immunostaining protocol included deparaffinization and
pH 9 epitope retrieval for 20 min, peroxidase blocking for
5 min, primary antibody incubation for 15 min, post-primary
rabbit anti-mouse IgG for 8 min, polymer anti-rabbit Poly-
HRP-IgG for 8 min, diaminobenzidine chromogen for
10 min, and hematoxylin counterstain for 5 min. Positive
and negative controls were included in all reactions.
Evaluation of immunoreactivity
Immunoreactivity evaluation included not only the neoplastic
lesions (ECA, AIS) or non-neoplastic lesions in control
patients but the adjacent normal glandular epithelium as well,
if present. The presence of concurrent cervical intraepithelial
neoplasia was noted; however, these lesions were not included
in the immunoreactivity analysis. The histological patterns
were detected in the original, routine HE stained slides.
Immunoreactivity was evaluated semiquantitatively by
three independent board-certified pathologists with over
15 years of professional experience (expert 1: E.K., expert 2:
K.K., expert 3: A.O.). Cases were regarded as positive if they
were obviously positive by × 40 magnification and further
classified according to the percentage of cells with nuclear
staining: < 10% as focally positive B+^, 10–50% as partly
positive B++^, and > 50% as diffusely positive B+++^ [20].
The inter-expert agreement was determined using
Intraclass Correlation Coefficient (ICC) [21] for both the neo-
plastic and the non-neoplastic lesions ratings. Two-way mod-
el, absolute agreement type was applied; both single and av-
erage measurement reliability was calculated. The analysis
was run in MedCalc statistical software (version 13.0.0.0,
MedCalc Software bvba, Ostend, Belgium) [22].
For statistical analyses, the individual ratings per lesions
and normal glandular epithelium if present were transformed
into a binary overall score. Immunoreactivity of a lesion or
normal glandular epithelium was regarded Brobust^ if at least
two of the three experts rated either B++^ or B+++^.
Immunoreactivity was regarded as Bnegative/focally positive^
if at least two of the three experts rated either B−^ or B+^.
Adjacent normal glandular epithelium was included in analy-
ses if it was detected by at least two experts.
Neoplastic (ECA and AIS) and non-neoplastic lesion im-
munoreactivity overall scores were statistically compared
using Fisher’s exact test (MedCalc). P value was considered
statistically significant if under 0.05.
Diagnostic test capability (sensitivity, specificity, and pos-
itive and negative predictive value) of EZH2 overexpression
in distinguishing (a) neoplastic lesions from non-neoplastic,
(b) neoplastic lesions from normal endocervical epithelium,
and (c) neoplastic lesions from non-neoplastic lesions and
normal endocervical epithelium combined was evaluated also
using MedCalc.
Results
A total of 54 cases of endocervical neoplastic lesions (37
ECA, 17 AIS) were retrieved from the archive. In 12 out of
these cases, concurrent HSILs were present. Concurrent LSIL
was present in one case. The median patient age was 44.5
(range 29–84). The most common IECC diagnoses were hu-
man papillomavirus–associated adenocarcinoma (HPVA)
type (92% of the cohort). Between subcategories, usual type
adenocarcinoma was the most common HPVA type (88% of
the cohort), followed by villoglandular, mucinous not
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otherwise specified (NOS), and mucinous including intestinal
and invasive stratified mucin-producing carcinoma (iSMILE)
categories (3%) (Table 1). There were only three patients with
nonhuman papillomavirus–associated adenocarcinoma
(NHPVA) (8%). Between subcategories, there were two cases
with serous type and one with the endometrioid type of
NHPVA.
The detailed results of the EZH2 immunohistochemical
analyses for ECA and AIS are summarized in Table 1 (for
ECA) and in Table 2 (for AIS).
Table 1 Clinical and immunostaining data of ECA cases
Case No. Age Diagnosis Type (IECC4) EZH2 immunoreactivity3
Normal glandular epithelium Neoplastic endocervical lesions
Expert Overall score9 Expert Overall score9
1 2 3 1 2 3
1. 83 ECA HPVA5/mucinous, intestinal ø2 ø ø ø +++ +++ +++ +
2. 84 ECA HPVA/usual – ø – – +++ +++ +++ +
3. 74 ECA HPVA/usual ø ø ø ø +++ +++ ++ +
4. 53 ECA + CIN31 HPVA/usual – + – – +++ +++ +++ +
5. 50 ECA NHPVA6/endometrioid – – – – + + ++ −
6. 48 ECA HPVA/usual ø ø – ø +++ ++ +++ +
7. 49 ECA + CIN3 HPVA/usual ø ø ø ø +++ +++ +++ +
8. 48 ECA HPVA/usual ø ø – ø +++ ++ ++ +
9. 42 ECA + AIS HPVA/usual + – – – +++ +++ +++ +
10. 45 ECA HPVA/usual – – – – +++ +++ +++ +
11. 37 ECA HPVA/usual – – – – +++ + +++ +
12. 41 ECA HPVA/villoglandular ø ø ø ø +++ +++ +++ +
13. 37 ECA HPVA/usual ø ø ø ø +++ +++ +++ +
14. 36 ECA+CIN2 HPVA/usual ø – – – ++ +++ ++ +
15. 30 ECA HPVA/usual – – – – +++ ++ +++ +
16. 31 ECA HPVA/usual – – – – +++ +++ +++ +
17. 90 ECA HPVA/usual ø ø ø ø +++ +++ +++ +
18. 43 ECA HPVA/usual ø ø – ø +++ +++ +++ +
19. 43 ECA HPVA/usual ø ø ø ø +++ +++ +++ +
20. 49 ECA HPVA/mucinous NOS7 ø ø – ø +++ +++ +++ +
21. 44 ECA HPVA/usual ø ø ø ø +++ +++ +++ +
22. 47 ECA HPVA/usual ø ø ø ø +++ +++ +++ +
23. 32 ECA HPVA/usual – – – – +++ +++ +++ +
24. 42 ECA HPVA/usual ø ø ø ø +++ +++ +++ +
25. 37 ECA HPVA/usual – – – – +++ +++ +++ +
26. 54 ECA HPVA/usual – – – – +++ +++ +++ +
27. 52 ECA HPVA/usual ø ø – ø +++ ++ +++ +
28. 50 ECA HPVA/usual ø ø – ø +++ +++ +++ +
29. 36 ECA HPVA/usual – – – – +++ +++ +++ +
30. 86 ECA HPVA/usual ø ø ø ø ++ ++ ++ +
31. 45 ECA HPVA/usual ø ø – ø +++ +++ +++ +
32. 36 ECA + CIN3 HPVA/usual – – – – +++ ++ +++ +
33. 41 ECA + AIS HPVA/iSMILE8 – – – – +++ +++ +++ +
34. 48 ECA NHPVA/serous – ø ø ø +++ +++ +++ +
35. 77 ECA NHPVA/serous – – – – +++ +++ +++ +
36. 47 ECA HPVA/usual – – – – +++ +++ +++ +
37. 37 ECA HPVA/usual – – – – +++ +++ +++ +
Endocervical adenocarcinoma
1 Cervical intraepithelial neoplasia
2 No normal glandular epithelium present on slide
3 Immunoreactivity extent: +++ = > 50%, ++ = 10–50%, + = < 10%, − = negative—no obvious immunoreactivity at × 40 magnification
4 International Endocervical Adenocarcinoma Criteria and Classification [19]
5 Human papillomavirus–associated adenocarcinoma
6Nonhuman papillomavirus–associated adenocarcinoma
7Mucinous, not otherwise specified
8 Invasive stratified mucin–producing carcinoma
9Overall score of immunoreactivity evaluation: B−^ refers to negative/focally positive (at least two experts rated either B−^ or B+^) while B+^ refers to robust
expression (at least two experts rated either B++^ or B+++^)
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All neoplastic endocervical lesions (ECA and AIS)
were found to be EZH2 positive by all three experts (for
details see Tables 1 and 2). Except for one case out of the
54, all of these lesions (98.14%) received a Brobust^ over-
all score.
Adjacent normal glandular epithelium was detected in
34 (63%) out of the 54 malignant cases by at least two
experts. On average, immunonegativity was found in
88.3%, while focal positivity in 11.7% of the detected
normal glandular epithelium samples by the three experts
(for details see Tables 1 and 2). Ratings resulted in an
overall score of Bnegative/focally positive^ in all of the
34 cases.
Figure 1 shows representative cases of diffuse (robust)
EZH2 immunoreactivity of the neoplastic endocervical le-
sions (ECA and AIS) and negative immunoreactivity of the
adjacent normal glandular epithelium.
A total of 32 non-neoplastic endocervical lesions (15 reac-
tive atypia, 9 microglandular hyperplasia, 3 tuboendometrioid
metaplasia, 3 tunnel cluster, 2 endometriosis) were analyzed.
The detailed results of the EZH2 immunohistochemical
analyses for non-neoplastic endocervical lesions were summa-
rized in Table 3.
On average, 67.7% of the ratings were negative, 24% of the
ratings were focally positive, and 8.3% of the ratings were
partly positive. The ratings resulted in an overall score of
Bnegative/focally positive^ in 28 out of the 32 cases (87.5%)
and Brobust^ in the rest of the cases (4 cases, 12.5%).
Adjacent normal glandular epithelium was detected in all
non-neoplastic endocervical lesion cases by all experts.
These adjacent normal glandular epithelium samples were
on average rated immunonegative in 95.84%, focally positive
in 2.08%, and partially positive in other 2.08% (for details see
Table 3). These ratings resulted in an overall score of Bnega-
tive/focally positive^ for each sample. Figures 2 and 3 show
representative cases of negative or focally positive (+) EZH2
immunoreactivity of the non-neoplastic lesions.
Fisher’s exact test yielded a statistically significant (two-
tailed p < 0.0001) difference in the overall immunoreactivity
scores between the neoplastic and non-neoplastic lesions
Table 2 Clinical and immunostaining data of AIS cases
Case No. Age Diagnosis EZH2 immunoreactivity3
Normal glandular epithelium Neoplastic endocervical lesions
Expert Overall score4 Expert Overall score4
1 2 3 1 2 3
1. 33 AIS – – – – +++ +++ +++ +
2. 53 AIS + CIN11 + + – – +++ +++ +++ +
3. 42 ECA + AIS + – – – +++ +++ +++ +
4. 41 AIS – – – – +++ +++ +++ +
5. 38 AIS – – – – +++ +++ +++ +
6. 35 AIS – – – – +++ +++ +++ +
7. 36 AIS – – – – +++ +++ +++ +
8. 31 AIS – – – – +++ +++ +++ +
9. 45 AIS + CIN3 ø2 ø – ø ++ ++ ++ +
10. 48 AIS + CIN3 – + – – +++ +++ +++ +
11. 46 AIS + CIN3 – – – – +++ +++ +++ +
12. 41 AIS + CIN3 – – – – +++ +++ +++ +
13. 45 AIS + CIN3 – – – – +++ +++ +++ +
14. 40 AIS + CIN3 – + – – +++ +++ +++ +
15. 41 ECA + AIS – – – – +++ +++ +++ +
16. 38 AIS + CIN3 – + – – +++ +++ +++ +
17. 65 AIS + CIN3 – – – – +++ +++ +++ +
Adenocarcinoma in situ
1 Cervical intraepithelial neoplasia
2 No normal glandular epithelium present on slide
3 Immunoreactivity extent: +++ = > 50%, ++ = 10–50%, + = < 10%, − = negative—no obvious immunoreactivity at × 40 magnification
4Overall score of immunoreactivity evaluation: B−^ refers to negative/focally positive (at least two experts rated either B−^ or B+^) while B+^ refers to
robust expression (at least two experts rated either B++^ or B+++^)
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(Brobust^ score was found in 53 out of the 54 neoplastic le-
sions vs. in 4 out of the 32 non-neoplastic lesions).
Robust EZH2 expression was found to have a sensitiv-
ity of 98.15% (95% CI = 90.11 to 99.95%) and a specific-
i t y o f 87 . 5% (95% CI = 71 .01 t o 96 . 49%) i n
distinguishing neoplastic lesions from non-neoplastic le-
sions, with a positive predictive value of 92.98% (95%
CI = 83 to 98.05%) and a negative predictive value of
96.55% (95% CI = 82.24 to 99.91%). A sensitivity of
98.15% (95% CI = 90.11 to 99.95%) and a specificity of
100% (95% CI = 94.4 to 100%) were found in
distinguishing neoplastic lesions from all normal glandu-
lar epithelium samples (n = 66), with a positive predictive
value of 100% (95% CI = 93.28 to 100%) and a negative
predictive value of 98.46% (95% CI = 91.72 to 99.96%).
A sensitivity of 98.15% (95% CI = 90.11 to 99.95%) and
a specificity of 95.88% (95% CI = 89.78% to 98.87%)
were found in distinguishing neoplastic from non-
neoplastic lesions and normal endocervical epithelium
samples combined (n = 98), with a positive predictive val-
ue of 92.98% (95% CI = 83 to 98.05%) and a negative
predictive value of 98.46% (95% CI = 94.17 to 99.97%).
For the neoplastic endocervical lesion (ECA and AIS) im-
munoreactivity ratings, inter-expert ICCs were 0.53 for single
measures (95% confidence interval = 0.37–0.67) and 0.77 for
average measures (95% confidence interval = 0.64–0.86).
For the non-neoplastic endocervical lesion immunoreactiv-
ity ratings, inter-expert ICCs were 0.8 for single measures
(95% confidence interval = 0.68–0.89) and 0.92 for average
measures (95% confidence interval = 0.86–0.96).
Discussion
The aim of this study was to investigate the EZH2 expression
status of neoplastic endocervical lesions such as ECA and AIS
compared with normal glandular epithelium and non-
neoplastic endocervical lesions.
All endocervical neoplastic lesions in this study were found
to be EZH2 positive by all experts. Moreover, immunoreac-
tivity was found to be very extensive. Except for one case, all
(98.14%) neoplastic lesions showed a robust EZH2
expression.
In contrast, robust EZH2 expression was significantly less
often (4 out of 32 cases, 12.5%) found in the non-neoplastic
glandular lesions (two-tailed p < 0.0001) and never (0 out of
66 samples) in the adjacent normal glandular epithelium.
Fig. 1 EZH2 nuclear expression in CIN, AIS, and ECA. a Diffuse
positive (robust) expression of EZH2 in CIN3 and AIS, negative
staining of EZH2 in normal endocervical glandules (Table 2; Case No.
11; immunohistochemistry; × 100 magnification). b Diffuse positive
(robust) expression of EZH2 in AIS (Table 2; Case No. 17;
immunohistochemistry; ×300 magnification). c–d Diffuse positive
(robust) nuclear expression of EZH2 in ECA (Table 1; Case No. 22.;
immunohistochemistry; × 200 and × 400 magnification)
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Occasionally, false positivity was caused by squamous meta-
plasia or reserve cell hyperplasia (e.g., in Fig. 2 case b).
Robust EZH2 expression appeared to have an excellent
diagnostic test capability in differentiating neoplastic lesions
from non-neoplastic lesions and normal endocervix. A sensi-
tivity of 98.15% and a specificity of 95.88% were found in
distinguishing neoplastic from non-neoplastic lesions and
normal endocervical epithelium samples combined (n = 98),
with a positive predictive value of 92.98% and a negative
predictive value of 98.46%.
Inter-observer agreement for average measurements could
be interpreted as excellent [23].
Our presented data suggest that EZH2 plays a role in the
pathogenesis of not only malignancies of the breast [7], lung
Table 3 Clinical and immunostaining data of non-neoplastic cases
Case No. Age Diagnosis EZH2 immunoreactivity2
Normal glandular epithelium Non-neoplastic endocervical lesions
Expert Overall score3 Expert Overall score3
1 2 3 1 2 3
1. 33 Reactive atypia – – – – – – – –
2. 50 – – – – + + – –
3. 39 – – – – – – – –
4. 54 – – – – + + + –
5. 40 – – – – + + – –
6. 40 – – – – – – – –
7. 42 – – – – – – – –
8. 39 ++ – – – ++ ++ + +
9. 49 ++ – – – ++ ++ + +
10. 43 – – + – + + + –
11. 32 – – – – – – – –
12. 46 – – – – + – + –
13. 61 – – – – – – – –
14. 48 – – – – – – – –
15. 48 – – – – – – – –
16. 51 Microglandular hyperplasia – – + – – – – –
17. 50 – – – – – – – –
18. 37 – – – – – – – –
19. 69 – – – – + + + –
20. 37 – – – – – – – –
21. 54 – – – – + + + –
22. 37 – – – – – – – –
23. 48 – – – – – – + –
24. 51 – – – – – – – –
25. 35 Endometriosis – – – – – – – –
26. 33 – – – – – – – –
27. 36 TEM1 – – – – – – – –
28. 41 – – – – ++ ++ + +
29. 46 – – – – – – – –
30. 61 Tunnel cluster – – – – – – – –
31. 53 – – – – ++ ++ + +
32. 67 – – – – – – – –
1 Tuboendometrioid metaplasia
2 Immunoreactivity extent: ++ = 10–50%, + = < 10%, − = negative—no obvious immunoreactivity at × 40 magnification
3Overall score of immunoreactivity evaluation: B−^ refers to negative/focally positive (at least two experts rated either B−^ or B+^) while B+^ refers to
robust expression (at least two experts rated either B++^ or B+++^)
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[8], stomach [9], colon [10], pancreatobiliary tract [11], liver
[12], thyroid gland [13], prostate [14], bladder [15], endome-
trium [16], and ovary [17] but also in endocervical neoplasia
as well. Since EZH2 expression was found in all investigated
cases including the non-human papillomavirus–related ones,
authors speculate that EZH2 is a substantial and independent
factor in endocervical carcinogenesis.
Yuting Gu et al. [24] studied the expression of EZH2 in
endometrial carcinomas. The expression rate of EZH2 in en-
dometrial carcinoma tissue (68.27%) was significantly higher
than that in adjacent tissue (24.03%). Nan Jia et al. [25] dem-
onstrated that EZH2 was overexpressed (medium to strong
reactivity) in complex hyperplasia, atypical hyperplasia, and
endometrial cancer, but not in simple hyperplasia and normal
endometrium (with negative to weak expression). In the study
by Jin et al., aberrant overexpression of EZH2 was frequently
observed in cervical squamous cell carcinoma as compared
with adjacent normal tissues (P = 0.0005). Although these
studies investigated immunoreactivity intensity, unlike immu-
noreactivity extent as in the present study, the results appear to
be still comparable. EZH2 immunoreactivity differences be-
tween neoplastic and non-neoplastic and/or normal tissues
appear to be at least as appreciable in the endocervix as in
the endometrium or cervical squamous epithelium. This raises
that EZH2 staining might be applied as a differential diagnos-
tic tool in endocervical lesions. At present, panels including
Fig. 2 Reactive atypia, microglandular hyperplasia, and endometriosis
with HE. a1, b1 (× 400 magnification), c1 (× 200 magnification). a2
EZH2 focal positivity in reactive atypia (Table 3; Case No. 10;
immunohistochemistry; × 400 magnification). b2 No expression of
EZH2 in microglandular hyperplasia, EZH2 focal positivity in
squamous metaplasia (Table 3; Case No. 24; immunohistochemistry; ×
400 magnification). c2 Negative staining of EZH2 in endometriosis
(Table 3; Case No. 25; immunohistochemistry; × 200 magnification)
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combinations of various markers are suggested for
endocervical differential diagnosis. Sandra Lee et al. [26]
showed that p16, p16/Ki67 dual stain, ProExC, CEA, ESA,
HIK1083, Claudin 18, and ER losses in perilesional stromal
cells were useful with high (≥ 0.75) sensitivity and specificity
estimates in ≥ 1 malignant versus benign comparisons. Our
data indicate that robust expression of EZH2 alone has an
even higher diagnostic reliability, with a sensitivity and spec-
ificity of over 95%.
As a conclusion, EZH2may play a role in the pathogenesis
of endocervical neoplasia, and the detection of robust expres-
sion of EZH2 might be a useful differential diagnostic tool in
problematic endocervical lesions in histology and probably in
cytology as well.
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